KRAS and lung cancer: In addition, combined inhibition of MEK and SHP2 showed high efficiency in engineered or xenograft KRAS-mutant pancreas, ovarian, and lung cancer [81, 83–85], overcoming the rapid resistance to MEK inhibitor as a single therapy.